ANN ARBOR, MICHIGAN – January 17, 2019 - Genomenon® has released a research report detailing the top emerging genomic variants in 2018. A variant is defined as a DNA mutation; this information is used in Precision Medicine to diagnose and treat disease. The report was compiled using the research data found in the Mastermind® Genomic Search Engine.
Compared to the 2017 Variant Report, this year’s data showed a continued trend of studies and new discoveries detailing variants that are becoming increasingly resistant to drugs. Also notable: an increasing number of emergent variants were found in non-cancer diseases.
The report includes:
The data reveals:
The Mastermind Genomic Search Engine is an evidence-based interpretation tool which provides immediate insight into the full text of millions of genomic articles and supplemental data for every disease, gene, and variant found in the literature. Mastermind is used by hundreds of diagnostic labs around the world to accelerate genomic interpretation, and by pharmaceutical companies to provide a comprehensive genomic landscape for any disease. The report is available here: Genomenon Research Report: Emerging Genomic Variants in 2018
This report was also posted on EnlightenBio in cooperation with its founder, Brigitte Ganter.
About Genomenon
Genomenon powers evidence-based genomics for faster; more comprehensive diagnosis and treatment decisions. Their flagship product, the Mastermind Genomic Search Engine provides immediate insight into the published genomic research for every disease, gene, and variant found in the literature.
Used by hundreds of diagnostic labs around the world, Mastermind accelerates genomic interpretation by providing unique insight into genomic relationships found in the full text of millions of scientific articles.
Pharmaceutical researchers license the Mastermind database for a comprehensive genomic landscape associated with any given disease – to identify and prioritize genomic biomarkers for drug discovery and clinical trial targets. For more information, visit www.genomenon.com.
The Real-world Evidence to validate a drug target, identify trial-eligible patients, or change a diagnosis already exists. It is buried in 39 million biomedical articles, locked behind paywalls and supplemental files most researchers never find.
Genomenon closes that gap. Fit-for-purpose AI-powered search reads 11.2 million full-text papers and 3.7 million supplemental datasets. Eighty expert scientific curators validate every finding. The result is structured, traceable, regulatory-grade Real-World Evidence at the genetic variant and patient level. Loxo@Lilly used Genomenon to add 73 variants to the RET label. In a head-to-head, Genomenon identified 83% more rare disease patients than ChatGPT plus OpenEvidence.
250+ diagnostic labs and 75 biopharma programs rely on Genomenon as the evidence layer behind precision medicine.
